Eisai's experimental Alzheimer's drug shows no signs of brain bleeding

Eisai unveiled much-anticipated findings on its experimental Alzheimer's drug, providing tinder for the hot debate over whether its modest efficacy is worth serious brain bleeding.

Lecanemab, developed with help from Biogen, pulled large amounts of an Alzheimer s-linked protein from the brain while slowing decline in mental capabilities and daily activities by 27% over 18 months, according to a commonly used rating scale. This came at the cost of brain swelling and bleeding that occurred in approximately 22% of people on the drug, compared to 10% of those who received a placebo.

The results are the main event at the Clinical Trials on Alzheimer's Disease conference in San Francisco and mark the first time that a drug aimed at slowing the brain disease has produced unambiguously positive results in a final stage trial.

It could be related to a conflict with your ad blocking or security software. You can add jp and piano.io to your list of allowed sites. If this does not resolve the issue or you are unable to add the domains to your allowlist, please see this FAQ. We humbly apologize for the inconvenience.